IMM-65 is under clinical development by Portage Biotech and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMM-65’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMM-65 is under development for the treatment of solid tumors including, bladder cancer and ovarian cancer. The drug candidate is a nanoparticle which is a combination of iNKT agonist and NY-ESO-1 tumor vaccine.
Portage Biotech overview
Portage Biotech (Portage), formerly Bontan Corporation Inc, is a clinical- stage immune-oncology company. The company’s portfolio includes PORT-2 and PORT-3-iNKT agonists for the treatment of melanoma, solid tumors, NY-ESO-1 positive tumors, and NY-ESO-1 bladder and ovarian cancers; PORT-1 intratumoral amphiphilic formulations against early-stage breast and pancreatic cancer, sarcoma, cholangiocarcinoma, squamous cell, PORT-4-Nanolipogel formulations targeting solid tumors; and PORT-5-STING agonist with VLP delivery for solid tumors. Portage utilizes the invariant natural killer T-cells (iNKT cells) platform to develop treatments for cancer. The company is also investigating PORT-6 and PORT-7, adenosine inhibitors to treat A2A and A2B solid tumors. Portage Biotech is headquartered in Toronto, Ontario, Canada.
For a complete picture of IMM-65’s drug-specific PTSR and LoA scores, buy the report here.